11/20
12:04 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Adicet Bio, Inc. (NASDAQ: ACET) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/18
04:00 pm
acet
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Medium
Report
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
11/18
12:38 pm
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
11/18
07:24 am
acet
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases [Yahoo! Finance]
Low
Report
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases [Yahoo! Finance]
11/18
07:00 am
acet
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
Medium
Report
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
11/18
06:57 am
acet
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Medium
Report
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
11/16
09:06 am
acet
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 [Yahoo! Finance]
Low
Report
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 [Yahoo! Finance]
11/16
09:00 am
acet
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Low
Report
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
11/6
04:00 pm
acet
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/5
07:00 am
acet
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
Low
Report
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
11/1
07:00 am
acet
Adicet Bio to Participate in Upcoming Investor Conferences
Medium
Report
Adicet Bio to Participate in Upcoming Investor Conferences
10/31
05:31 pm
acet
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/16
02:34 pm
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
10/16
11:29 am
acet
Adicet Bio gets FDA clearance of IND amendment for stiff person syndrome treatment [Seeking Alpha]
Medium
Report
Adicet Bio gets FDA clearance of IND amendment for stiff person syndrome treatment [Seeking Alpha]
10/16
07:00 am
acet
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
Medium
Report
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
10/8
11:12 pm
acet
Adicet Bio, Inc. (NASDAQ: ACET) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Adicet Bio, Inc. (NASDAQ: ACET) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/1
07:36 am
acet
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy [Yahoo! Finance]
Low
Report
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy [Yahoo! Finance]
9/30
05:08 pm
acet
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
9/30
04:36 pm
acet
Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference [Yahoo! Finance]
Neutral
Report
Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference [Yahoo! Finance]
9/30
04:30 pm
acet
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
Neutral
Report
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
9/30
02:03 pm
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
9/30
09:01 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) is now covered by analysts at Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) is now covered by analysts at Guggenheim. They set a "buy" rating and a $7.00 price target on the stock.
9/30
07:00 am
acet
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
Low
Report
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
9/20
09:13 am
acet
Adicet Bio, Inc. (NASDAQ: ACET) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Adicet Bio, Inc. (NASDAQ: ACET) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
9/19
05:44 pm
acet
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight [Yahoo! Finance]
Low
Report
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight [Yahoo! Finance]